Abstract:The natural history of COPD is complex, and the disease is best understood as a syndrome resulting from numerous interacting factors throughout the life cycle with smoking being the strongest inciting feature. Unfortunately, diagnosis is often delayed with several longitudinal cohort studies shedding light on the long 'preclinical' period of COPD. It is now accepted that individuals presenting with different COPD phenotypes may experience varying natural history of their disease. This includes its inception, early stages and progression to established disease. Several scenarios regarding lung function course are possible, but it may conceptually be helpful to distinguish between individuals with normal maximally attained lung function in their early adulthood who thereafter experience faster than normal FEV1 decline, and those who may achieve a lower than normal maximally attained lung function. This may be the main mechanism behind COPD in the latter group, as the decline in FEV1 during their adult life may be normal or only slightly faster than normal. Regardless of the FEV1 trajectory, continuous smoking is strongly associated with disease progression, development of structural lung disease and poor prognosis. In developing countries, factors such as exposure to biomass and sequelae after tuberculosis may lead to a more airway‐centred COPD phenotype than seen in smokers. Mechanistically, COPD is characterized by a combination of structural and inflammatory changes. It is unlikely that all patients share the same individual or combined mechanisms given the heterogeneity of resultant phenotypes. Lung explants, bronchial biopsies and other tissue studies have revealed important features. At the small airway level, progression of COPD is clinically imperceptible, and the pathological course of the disease is poorly described. Asthmatic features can further add confusion. However, the small airway epithelium is likely to represent a key focus of the disease, combining impaired subepithelial crosstalk and structural/inflammatory changes. Insufficient resolution of inflammatory processes may facilitate these changes. Pathologically, epithelial metaplasia, inversion of the goblet to ciliated cell ratio, enlargement of the submucosal glands and neutrophil and CD8‐T‐cell infiltration can be detected. Evidence of type 2 inflammation is gaining interest in the light of new therapeutic agents. Alarmin biology is a promising area that may permit control of inflammation and partial reversal of structural changes in COPD. Here, we review the latest work describing the development and progression of COPD with a focus on lung function trajectories, exacerbations and survival. We also review mechanisms focusing on epithelial changes associated with COPD and lack of resolution characterizing the underlying inflammatory processes.

Unveiling mechanisms of lung aging in COPD: A promising target for therapeutics development

Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease

Targeting accelerated pulmonary ageing to treat chronic obstructive pulmonary disease-induced neuropathological comorbidities

[Cell senescence and pathophysiology of chronic lung diseases: role in chronic obstructive pulmonary disease]

Aging Lung: Molecular Drivers and Impact on Respiratory Diseases—A Narrative Clinical Review

An Atlas of the Aging Lung Mapped by Single Cell Transcriptomics and Deep Tissue Proteomics

Epigenetic blood biomarkers of ageing and mortality in COPD

DNA damage response at telomeres contributes to lung aging and chronic obstructive pulmonary disease

Aging in chronic lung disease: Will anti-aging therapy be the key to the cure?

Lung tissue gene-expression signature for the ageing lung in COPD

Accelerated epigenetic aging as a risk factor for chronic obstructive pulmonary disease and decreased lung function in two prospective cohort studies

Multi-modal transcriptomic analysis reveals metabolic dysregulation and immune responses in chronic obstructive pulmonary disease

Sirtuin 1 and Aging Theory for Chronic Obstructive Pulmonary Disease

Cell Proliferation and Apoptosis—Key Players in the Lung Aging Process

Pathogenesis of COPD 4 – Cell Death, Senescence, and Autophagy: Is There a Possibility of Developing New Drugs from the Standpoint of This Pathogenetic Mechanism?

Aging and Susceptibility to Pulmonary Disease.

Impact of aging on immune function in the pathogenesis of pulmonary diseases: potential for therapeutic targets

[Research Progress of Lung Aging in Chronic Respiratory Diseases].

Natural history and mechanisms of COPD

Suppressed Expression of T-Box Transcription Factors Is Involved in Senescence in Chronic Obstructive Pulmonary Disease

Targeting cellular senescence: A promising approach in respiratory diseases